Travaux subventionnés

Retour aux résultats

Neuromodulation of the posterior hypothalamus as a potential novel therapy for drug-resistant temporal lobe epilepsy

Aperçu du projet

Epilepsy is a severe neurological disorder that affects approximately 300,000 Canadians. Temporal lobe epilepsy is the most common form of epilepsy in adults and is characterized by seizures that cause abnormal sensations, impaired consciousness, and loss of motor control. Anti-seizure medications are the main treatment strategy for patients with epilepsy, but 1 in every 3 patients experience drug-resistant epilepsy. Therefore, a major goal of our research program is to identify new and effective treatment strategies for patients with drug-resistant epilepsy. Preliminary data from our laboratory has found that a brain region known as the hypothalamus influences seizure frequency in mouse models of epilepsy. In the present study, we plan to test whether modifying the activity of the hypothalamus with brain stimulation procedures can reduce seizures in mice and human patients with drug-resistant epilepsy. Our findings could lead to the discovery of new therapies for people living with drug-resistant epilepsy.

Chef d'équipe

Justin Botterill , University of Saskatchewan

Partenaire et Donateurs

Saskatchewan Health Research Foundation

Projet en cours

Neuromodulation of the posterior hypothalamus as a potential novel therapy for drug-resistant temporal lobe epilepsy

  • Type de subvention

    Team grants

  • Domaine de recherche

    Central Nervous System

  • Disease Area

    Epilepsy

  • Compétition

    2025-2026 Solutions Program Innovation + Impact Grants

  • Province

    Saskatchewan

  • Date de Début

    2026

  • Montant total du financement

    $150,000

  • Contribution Santé Canada

    $75,000